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Abstract
Human cell-based assays for in vitro testing of drugs in preclinical and research
studies, as well as in clinical practice, are gaining greater importance especially in
view of personalized medicine, which is tailored to the individual needs and benefits
of a patient. This chapter begins with an overview of contemporary cell-based assays,
routinely used for a comparative in vitro potency testing of anti-TNF-α innovator
biologics and their biosimilars. In sequel, based on the results of our original work,
we will further discuss the establishment and use of 2D normal and osteoarthritic
primary chondrocyte monolayer cultures and 3D microspheroidal articular cartilage
tissues, prepared in hanging drops from osteoarthritic chondrocytes and
chondrogenically differentiated mesenchymal stem cells. Both 2D and 3D cultures
will be presented as models for assessing the neutralizing potency of the three well-
known anti-TNF-α biological drugs: adalimumab, etanercept, and infliximab.
Keywords: in vitro cell-based assays, anti-TNF-α biologics, human articular
chondrocytes, mesenchymal stem cells, 2D monolayer cultures, 3D cell cultures,
gene expression
1. Introduction
Following the discovery and characterization of tumor necrosis factor (TNF) in
the mid-1980s, this pleiotropic proinflammatory cytokine continues to be the focus of
numerous studies and represents an important therapeutic target [1, 2]. The venue of
anti-TNF biological drugs has revolutionized treatment of autoimmune and inflam-
matory diseases like rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing
spondylitis, psoriasis, Crohn’s disease, ulcerative colitis, and others [2]. Although
expensive, biological drugs (biologics) at the moment represent the best-selling
group of pharmaceuticals. Nowadays, following the expiry of originators patents, a
plethora of less expensive biosimilar drugs (biosimilars) are available to patients. In
order to confirm the biocomparability of original and biosimilar products and to
prove their quality, safety, and efficacy, the use of reliable and standardized bioassays
relevant in assessing their modes of action is of crucial importance.
In this chapter, after a short introductory review of TNF biology, anti-TNF
biological drugs and their mechanisms of action, we will present a selection of
in vitro cell-based tests used either for general or personalized potency testing of
anti-TNF biologics and their biosimilars.
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2. A short overview of TNF biology
TNF is produced in various cell types, mainly immune cells such as monocytes
and macrophages, microglia, neutrophils, natural killer cells (NK), T lymphocytes,
and also in neuronal cells, keratinocytes, and fibroblasts [2, 3]. The cytokine exists
in two biologically active forms. The first being a transmembrane protein (tmTNF),
which can be cleaved by the metalloproteinase TNF-α-converting enzyme (TACE)
(also known as disintegrin and metalloproteinase domain-containing protein 17
(ADAM17)) into its second form, a homotrimeric soluble TNF (sTNF) [2].
There are two TNF-binding homotrimeric transmembrane receptors, namely the
TNF receptor 1 (TNFR1 or CD120a) and the TNF receptor 2 (TNFR2 or CD120b) [2].
While the TNFR1 is constitutively expressed on a vast majority of nucleated cells, the
TNFR2 expression is inducible and tightly regulated, preferentially on endothelial,
hematopoietic, neural, and immune cells [2, 4]. TNFR2 is also expressed on tumor
cells where it is supposed to function as a tumor oncogene [5, 6].
Interestingly, tmTNF can induce signals in a bipolar way, as it acts as a ligand of
both receptor types and as a receptor itself in cell-to-cell contacts [2, 4]. This means
that tmTNF-α-expressing cells transmit signals to cells bearing TNFR1 and/or
TNFR2. This phenomenon is called “outside-to-inside” or “reverse signaling,” the
function of which has not been completely clarified yet [2, 4]. The receptor func-
tion of tmTNF has been demonstrated in human monocytes, macrophages, NK
cells, and T lymphocytes [4].
While TNFR1 is activated by both tmTNF and sTNF, TNFR2 can only be trig-
gered by tmTNF. Both types of membrane-bound receptors are prone to TACE
cleavage, resulting in fragments termed soluble TNF receptors (sTNFR) [2]. In
turn, sTNFR may contribute to the regulation of cellular TNF responses by captur-
ing and neutralizing circulating TNF (intrinsic TNF inhibitors). Additionally, due to
increased receptor shedding, the number of functional signaling membrane TNFRs
decreases. Consequently, this leads to a state of transient TNF desensitization [2].
3. Anti-TNF biological drugs and their mechanisms of action
Among currently available Food and Drug Administration (FDA)- and Euro-
pean Medicines Agency (EMA)-approved originator and biosimilar anti-TNF drugs,
there are three full-length monoclonal antibodies (mAbs); these are infliximab
(IFX), a chimeric mouse/human mAb (Remicade® and its biosimilars: Remsima®,
Inflectra®, Flixabi®, Ixifi®, Renflexis®, and Zessly®), adalimumab (ADA), a fully
humanized mAb (Humira® and its biosimilars: Cyltezo®, Imraldi®, Amgevita®,
Solymbic®, Hyrimoz®, Hulio®, Halimatoz®, and Heyifa®), and golimumab,
another fully humanized mAb (Simponi®) (Figure 1) [2, 4]. The additional two
anti-TNF biological drugs, which are not mAbs, are etanercept (ETA) (Enbrel® and
its biosimilars: Erelzi® and Benepali®), a fusion protein consisting of two extracel-
lular parts of the human TNFR2 and the Fc portion of human IgG1, and
certolizumab pegol (Cimzia®) composed of a human Fab’ fragment, covalently
attached to two cross-linked 20 kDa polyethylene glycol chains (Figure 1) [2, 4].
Although all anti-TNF biologics neutralize the same target (sTNF and tmTNF),
they are not equally effective in treatment of certain inflammatory pathologies, for
example, Crohn’s disease. This is due to differences in their characteristics (struc-
ture and binding affinities) and mechanisms of action (Figure 1) [2, 4]. Besides all
of them being efficacious in neutralizing both forms of TNF, infliximab additionally
induces “outside-to-inside” signaling via binding to tmTNF, thereby triggering
apoptosis of tmTNF-expressing immune cells [2]. Being full-length mAbs,
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chondrogenic tissue model which, combined with the qRT-PCR readout method,
can be used for preclinical or patient-specific potency assessment of anti-TNF-α and
anti-interleukin-1β biological drugs (anti-IL-1β) [26]. For establishing this model,
we used human OACs and chondrogenically differentiated MSCs.
As already stated, OACs represent an attractive source of cells for cell-based
models as besides being rather easily accessible and free of ethical concerns, they
are also genetically stable during their long-term in vitro expansion [36, 37]. Reports
show that MSCs isolated from bone marrow of OA patients are capable of produc-
ing hyaline cartilage suitable for tissue repair. MSCs obtained from OA and RA
patients possess similar chondrogenic potential as those from healthy individuals
[38–41]. Therefore, we used paired samples of MSCs and OACs from two donors
and a set of genetically mismatched biological samples of patient’s OACs and com-
mercially available MSCs. The paired cell sampling approach allowed us to reduce
the high patient-to-patient variability, which influences the chondrogenic potential
of both OACs and MSCs [42].
Among the numerous commercially available 3D cell culture systems, we have
chosen Perfecta 3D® scaffolds (3D Biomatrix Inc., USA) to create tissues in hanging
drops. Generation of scaffold-free spheroids of micrometric dimensions
(microspheroids) by gravity-enforced self-assembly in hanging drops allows cell
aggregation and tissue formation in a natural manner, without interference from
the scaffold material [19, 32]. This technique has important advantages, especially
the drop size control and consequent uniformity of formed microspheroids. More-
over, it is compatible with automated liquid handling systems, a prerequisite for
high-throughput screening in drug discovery. The microspheroid formation in
hanging drops mimics the condensation process of MSCs, which is one of the
earliest phases of in vivo cartilage development [32].
Isolated OACs were first expanded in 2D monolayer cultures and then, from
passage 2 and on, 10,000 cells were transferred into each hanging drop. In this way,
the loss of chondrogenic phenotype of OACs in 2D was restored in 3D conditions, as
already reported [30, 43]. Similarly as in our previously described 2D primary
chondrocyte model, the TNF-α neutralizing efficiencies of ADA (Humira®, Abbott
Laboratories, USA), ETA (Enbrel®, Immunex Corp., USA), IFX (Remicade®,
Janssen Biotech, USA), and the anti-IL-1β drug anakinra (ANA; Kineret®, Swedish
Orphan Biovitrum AB, Sweden) were assessed with both cell types by determining
the extent of downregulation of six selected genes (IL6, IL8,MCP1,MMP1,MMP13,
and VCAM1) [27, 28]. Gene expression was determined after a 24 h incubation of
microspheroids in a medium supplemented with 1 ng/mL of an appropriate inflam-
matory cytokine (rhTNF-α or rhIL-1β; both from PeproTech, USA) or working
macrophage conditioned medium (MCM) solution, combined with 1 μg/mL of each
individual biological drug tested (Figure 4).
According to our criteria, Log2 RQ ≥1 and ≤1, TNF-α significantly upregulated
the expression of IL6, IL8, MCP1, MMP1, MMP13, and VCAM1 genes in the 3D
microspheroidal model as well (Figure 4a). The same was true when IL-1β or MCM
was added to microspheroids. MCM was obtained from cell cultures of the human
monocytic cell line THP-1 (ATCC, USA) and represented a rich source of inflam-
matory cytokines with 0.05 ng/mL TNF-α and 0.45 ng/mL IL-1β, and numerous
other growth factors. In terms of influencing gene expression, IL-1β was the most
potent inflammation inducer, followed by MCM and then TNF-α. The inflamma-
tory process triggered by each of these three inducers could always be reversed by
ADA, IFX, or ETA, as well as ANA (Figure 4a). When inflammation was triggered
by TNF-α, all tested anti-TNF-α biologics extraordinarily suppressed the expression
of monitored genes, sometimes even reaching their constitutively expressed levels
(log2 RQ = 0). Similarly, in the presence of IL-1β, ANA markedly reversed the
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inflammation process in microspheroids. However, when microspheroids were
incubated with MCM, none of the three tested anti-TNF-α drugs were successful in
diminishing its inflammatory effect. Conversely, ANA could downregulate the
expression of IL6, IL8, and MMP1 genes. The described changes at the gene level
were accompanied by significant differences in the expression of IL6, IL8, and
MCP1 proteins, detected in supernatants of microspheroid cultures, 24 h after their
incubation with a given inflammatory agent  selected anti-inflammatory biologi-
cal drug [26]. Moreover, these results were additionally supported by the amount of
glycosaminoglycans present in chondral spheroids composed of 100,000 OACs
treated with various combinations of a particular inflammatory agent  a given
anti-inflammatory biologic, for a period of 3 weeks.
When microspheroids were incubated with MCM, a superior anti-IL-1β neutral-
ization capacity of ANA compared to the three tested anti-TNF-α biologics was
observed. This difference was probably due to the fact that MCM contained a much
Figure 4.
(a) Gene expression profiles following the addition of inflammatory mediators TNF-α, IL-1β, or MCM
working solution and anti-inflammatory biological drugs ADA, IFX, ETA, and ANA. Blue and green dots
represent values obtained in microspheroidal chondral tissues made of MSCs and OACs (three donors),
respectively. Statistically significant changes, that is, Log2 RQ ≥1 and ≤1 are outlined with median values for
all groups. (b) Radar graphs representing anti-TNF-α neutralization efficacies of ADA (blue), IFX (red), and
ETA (green). Mean RQ values of three biological samples are shown for OAC- and MSC-derived
microspheroids. Value 0 in the center of each radar graph represents total inhibition of gene expression. Original
figure used with authors’ permission under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/) [26].
11
In vitro Cell-Based Assays for Potency Testing of Anti-TNF-α Biological Drugs
DOI: http://dx.doi.org/10.5772/intechopen.85237
higher concentration of IL-1β (0.45 ng/mL) than TNF-α (0.05 ng/mL). Neverthe-
less, these concentrations of both cytokines are much higher than those measured in
synovial fluids of OA and RA patients (0.028 ng/mL TNF-α and 0.1 ng/mL IL-1β)
[44]. Although MCM proved to be an excellent in vitro inducer of inflammation, its
use for potency testing of anti-inflammatory biologicals targeting a specific cyto-
kine is questionable. In fact, from the multiple synergistic proinflammatory effects
evoked by different biogenic factors present in MCM, it is very hard to define the
potency of a biological targeting a single inflammatory factor.
In our 3D microspheroidal rhTNF-α-induced inflammation model, the neutrali-
zation capacity of ADA was superior over that of ETA and the even weaker IFX
(Figure 4b). Similar results were obtained with both microspheroids, regardless of
whether they were made of OACs or chondrogenically differentiated MSCs. The
observed differences in neutralizing efficiencies of ADA, ETA, and IFX can be
attributed to differences in their molecular structures and sTNF-α-binding affinities
[45]. The superior anti-TNF-α efficacy of ADA over ETA and IFX has already been
reported together with data, showing that the sTNF-α-binding affinity of ADA is
higher for ADA (Kd = 7.05  1011) than ETA (Kd = 2.35  1011) and IFX
(Kd = 1.17  1010) [46–48]. However, according to our criterion, a particular
biologic would be statistically more efficient than the compared one if it would
cause a ≥2-fold decrease in a selected gene expression. This was not the case in any
of our 3D microspheroidal model experiments. Consequently, we assumed that the
observed differences in TNF-α neutralizing potency of ADA, ETA, and IFX were
comparable (Figure 4b). Interestingly, although we showed in our 2D OACs model
that ETA was significantly more efficient than IFX, the same kind of experiments
carried out in a 3D microspheroidal model did not confirm this finding [26, 27]. We
assume that compared to the 2D model, the diffusion of tested biologics in our 3D
microspheroidal model was much slower and limited. Undoubtedly, the 3D model
better resembles in vivo conditions and therefore has a higher relevance. Thus, we
concluded that 2D cell culture models may be useful for obtaining preliminary data
regarding the anti-inflammatory effects of a particular biological drug, while 3D
microtissue models enable more relevant insights in drug-tissue interactions and
possible outcomes in vivo. The results obtained with our 3D microspheroidal model
are also supported by the outcomes of clinical studies conducted on patients with
RA, where the efficacies of anti-TNF-α biologics proved to be comparable [49].
We found that OACs and chondrogenically differentiated MSCs are suitable
sources for hanging drop chondral 3D microspheroid cultures formation, which are
useful for the assessment of neutralization potencies of anti-inflammatory biologics
[26]. Although the use of these two types of microspheroids resulted in different gene
expression profiles following their incubation with tested combinations of rhTNF-α,
and each of the three tested anti-TNF-α biological drugs (Figure 4b), these differ-
ences were rather small. Therefore, we concluded that MSCs can be used as an
alternative and probably even more accessible cell source for in vitro testing of
neutralization potency of anti-TNF-α biologics. The main advantages of our 3D
model are the use of small amounts of human cells and cytokines, personalized
testing approach, and the possibility of automation. In addition, the presented
approach can also be used as a platform for testing other anti-inflammatory biologics
with different mechanisms of action, as shown for ANA, the antagonist of IL-1β.
6. Conclusion
Cell-based assays are complex analytical tools, susceptible to multiple variables
that are virtually impossible to control. Therefore, they have to be precise, reliable,
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and well standardized so that the results are reproducible and can be compared
among different laboratories. When used for drug potency testing, such assays
usually rely on the use of reference standards. Recently, the WHO has prepared two
international standards for the two anti-TNF-α biologics, etanercept and infliximab.
These have been tested by several laboratories within an international collaborative
study using a number of different cell-based assays [12, 13]. In this chapter, we have
presented an overview of the most routinely used tests for potency testing of anti-
TNF-α biologics, which measure in vitro responses of nonmanipulated or genetically
engineered human and animal cell lines, with various readout systems.
Nowadays, with an expanding personal medicine approach, laboratory assay-
guided pharmacotherapeutical strategies are becoming more and more important.
In order to obtain relevant data on drug potencies for a particular patient, these
kinds of tests should be based on the patient’s own, that is, autologous primary cells,
as these can significantly reduce costs and enable safer and more effective therapies.
Therefore, we dedicated a part of this chapter to our experience in establishing
in vitro 2D monolayer cultures consisting of normal and OA chondrocytes and 3D
microspheroidal chondral tissues, formed from OACs or chondrogenically differ-
entiated bone-marrow-derived MSCs, and their use for testing anti-TNF-α efficacy
of adalimumab, etanercept, and infliximab. The qRT-PCR technique was applied as
a readout system for assessing differences in selected gene expressions. The
obtained data led us to the establishment of an original statistical method, which
was used for the evaluation and comparison of results.
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